PAION
Associated tags: Pharmaceutical industry, Remimazolam, Frankfurt Stock Exchange, ISIN, Anesthesia
Locations: ITALY, ASIA, BRAZIL, LATIN AMERICA, SCOTLAND, DEUTSCHLAND, , CHINA, HUBEI, USA, AFRIKA
EQS-News: PAION AG: Verkauf des Geschäftsbetriebes
EQS-News: PAION AG UNTERZEICHNET VEREINBARUNG ÜBER EINE STRATEGISCHE ZUSAMMENARBEIT MIT YICHANG HUMANWELL
EQS-News: PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD
This release contains certain forward-looking statements concerning the future business of PAION AG.
- This release contains certain forward-looking statements concerning the future business of PAION AG.
- These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG’s management as of the date of this release.
- PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.
- 22.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
EQS-News: PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS - PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED
The issuer is solely responsible for the content of this announcement.
- The issuer is solely responsible for the content of this announcement.
- Aachen (Germany), 31 October 2023 - The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that, in accordance with the ad hoc announcement dated October 26, 2023, it filed for the opening of insolvency proceedings with the Local Court of Aachen, Insolvency Court, on Friday, October 27, 2023.
- Furthermore, an insolvency petition was also filed by PAION AG's subsidiary PAION Deutschland GmbH.
- Attorney Dr. Mark Boddenberg has been appointed as the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH.
EQS-News: PAION AG hat Antrag auf Eröffnung des Insolvenzverfahren gestellt – vorläufiger Insolvenzverwalter bestellt
EQS-News: PAION AG beschliesst Ausgabe von rund 4,8 Mio. Aktien zu EUR 1,90 pro Aktie im Rahmen einer Bezugsrechtskapitalerhöhung
EQS-News: PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).
- For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).
- PAION will receive gross proceeds of about EUR 9 million for the capital increase with subscription rights.
- Tilmann Bur, CEO of PAION AG, commented: "This capital increase is an important step towards achieving our growth targets.
- Sebastian Werner, CFO of PAION AG, added: ”This capital increase marks a first important milestone in our overarching financing strategy.
EQS-News: PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
October 2023 - The Management Board of the specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) has today decided, with the approval of the Supervisory Board, to increase the share capital of the company by partially utilizing the authorized capital by way of a rights issue with target gross proceeds of EUR 10 million.
- October 2023 - The Management Board of the specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) has today decided, with the approval of the Supervisory Board, to increase the share capital of the company by partially utilizing the authorized capital by way of a rights issue with target gross proceeds of EUR 10 million.
- PAION AG will publish the securities prospectus on its website (www.paion.com) after its approval by BaFin.
- Tilmann Bur, CEO of PAION AG, commented: "This capital increase lays the foundation for future growth and a successful market entry of Byfavo® in general anesthesia in Europe.
- We are particularly encouraged by the commitment of Humanwell and Nice & Green to participate in this capital increase.